



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Massimiliano Filosto**

Organisation/Company: University of Brescia

Country: Italy

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
04/2019-04/2019	Sanofi Genzyme	Malaysia Pompe Disease Medical Advisory Board Meeting	
11/2020-11/2020	Alnylam	hATTR:screen and care	
03/2021-09/2021	Sanofi	Consensus: Late-onset Pompe disease in pediatric age	
06/2021-06/2021	Sanofi	Avalglucosidase alfa	Pompe Disease
06/2021-06/2021	Amicus	Amicus International Advisory Board on Pompe Disease	
04/2022-04/2022	Amicus	Amicus International Pompe Expert Forum	
05/2022-05/2022	Amicus	Amicus Advisory Board on outcome measures in Pompe Disease	
01/2022-(current)	Sanofi	Recognising adult late onset Pompe Disease in real life -Pompe Star	
01/2022-(current)	Sanofi	Pompe PED in real life: Malattia di Pompe non classica in età pediatrica: conoscerla per riconoscerla	

2.3 Strategic advisory role

No interest declared

Classified as public by the European Medicines Agency

2

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

Period	Company	Products	Therapeutic Indication
01/2019-09/2020	Biogen	BIB074	Small fiber neuropathies
04/2020-09/2020	Argenx	Efgartigimod with rHuPH20	CIDP
04/2020-09/2020	Eidos Therapeutics	AG10	Transthyretin Amyloid Polyneuropathy
11/2021-(current)	AB Science	masitinib	ALS
10/2022-(current)	Biohaven	BHV2000-301	Spinal Muscular Atrophy
10/2022-(current)	Stealth Biotherapeutics	Elamipretide	mitochondrial diseases

2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Sanofi	Research grant for a medical doctor

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

None

2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

Classified as public by the European Medicines Agency

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Massimiliano Filosto
Date:	2022-10-24

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template